Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study

Table 1 Patient characteristics by categorized tumor-stroma ratio

	TSR-low (n = 36)		TSR-intermediate (n = 70)		TSR-high (n = 48)		P-value1
	n	%	n	%	n	%
Gender							NS
Male	24	66.7	44	62.9	32	66.7
Female	12	33.3	26	37.1	16	33.3
Age (yr)	M 68.0	SD 8.0	M 67.3	SD 10.3	M 65.7	SD 10.3	NS2
	(range 49.0-82.0 )		(range 40.0-87.0)		(range 43.0-91.0)
Treatment							NS
APR	19	52.6	31	44.3	17	35.4
LAR	11	30.6	28	40.0	24	50.0
Hartmann	6	16.7	11	15.7	7	14.6
T-status							NS
pT1	1	2.8	1	1.4	4	8.3
pT2	9	25.0	23	32.9	18	37.5
pT3	24	66.7	43	61.4	25	52.1
pT4	2	5.6	3	4.3	1	2.1
N-status							0.029
pN0	16	44.4	44	62.9	34	70.8
N1	15	41.7	13	18.6	11	22.9
N2	5	13.9	13	18.6	3	6.3
Stage							NS
I	7	19.4	21	30.0	17	35.4
II	9	25.0	23	32.9	17	35.4
III	20	55.6	26	37.1	14	29.2
Grading							NS
Well	0	0	1	1.4	3	6.3
Moderate	31	86.1	58	82.9	40	83.3
Poor	5	13.9	11	15.7	5	10.4
Adjuvant treatment	19	52.8	21	30.0	11	22.9	0.0123
Radiotherapy	17		18		9
Chemoradiotherapy	1		3		2
Chemotherapy	1		-		-

¹Pearson χ² test;

²One-Way ANOVA;

³P-value for adjuvant treatment in general. Significant P-values are shown bold. n: Number of patients; %: Percentage; Age defined as period from birth until date of primary surgery; LAR: Low anterior resection; APR: Abdominoperineal resection; pT: Pathological tumor status; pN: Pathological nodal status; Stage according to UICC/AJCC TNM staging system, 5^th edition; TSR: Tumor-stroma ratio; UICC/AJCC: Union Internationale Contre le Cancer/American Joint Cancer Committee.